Amgen Signs a R&D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases

 Amgen Signs a R&D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases

Amgen Signs a R&D Collaboration with Neumora to Advance Novel Precision Therapies for Neuropsychiatric and Neurodegenerative Diseases

Shots:

  • Neumora has received a $100M as an equity investment and obtains an exclusive global right to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases
  • The collaboration will utilize Neumora’s precision neuroscience platform with Amgen’s deCODE human genetics capabilities to boost innovative therapies for the treatment of brain disease
  • Neumora’s precision neuroscience platform focuses on the Data Biopsy Signatures to develop the complex systems for brain diseases & develop therapies for an enriched patient population or Precision Phenotypes

Click here to read full press release/ article | Ref: PR Newswire | Image: Biospace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post